Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J310, Denver, CO 80206, USA.
Immunol Allergy Clin North Am. 2020 Nov;40(4):593-607. doi: 10.1016/j.iac.2020.06.004. Epub 2020 Sep 12.
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that has become a global health problem. The pathophysiology of AD includes both skin barrier and immune abnormalities, with type 2 immune deviation central to several clinical phenotypes and underlying endotypes. Recognition of the persistent nature and systemic aspects of AD provides a rationale for treatment with a biologic. Dupilumab has been approved for patients 6 years of age and older with moderate to severe AD. Monoclonal antibodies are in phase 3 trials and may become part of a precision medicine approach to AD.
特应性皮炎（AD）是一种常见的慢性炎症性皮肤病，已成为全球性的健康问题。AD 的病理生理学包括皮肤屏障和免疫异常，2 型免疫偏倚是几种临床表型和潜在表型的核心。对 AD 的持续性和系统性的认识为生物制剂治疗提供了依据。度普利尤单抗已获批准用于 6 岁及以上中重度 AD 患者。单克隆抗体正在进行 3 期临床试验，可能成为 AD 精准医学方法的一部分。
